A second phase III trial of brilacidin for the treatment of acute bacterial skin and skin structure infections

Trial Profile

A second phase III trial of brilacidin for the treatment of acute bacterial skin and skin structure infections

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cellceutix
  • Most Recent Events

    • 11 Feb 2016 New trial record
    • 09 Feb 2016 According to a Cellceutix media release, the company will be submitting an SPA request for the phase III trials of brilacidin for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top